Research Standards & Editorial Policy

How the Remy Peptides research library selects sources, verifies claims, and maintains accuracy across 45 articles covering retatrutide, tirzepatide, CagriSema, survodutide, and the broader obesity drug pipeline.

Research Team

The Remy Peptides research library is maintained by a team with backgrounds in pharmaceutical sciences, clinical research methodology, and bioanalytical chemistry. All articles are written by researchers with direct experience reading and interpreting Phase 2 and Phase 3 clinical trial data, FDA regulatory filings, and peer-reviewed publications in obesity pharmacology.

Content is reviewed for accuracy against primary sources before publication. Our editorial process prioritises verifiable claims over speculation, and we clearly distinguish between published clinical data and preliminary conference abstracts or company-reported results.

Research Director

Author Attribution

Articles in the research library are published under the Dr. Nadia Haroun byline and reviewed by Dr. Haroun (PharmD, Research Director). Individual contributor expertise spans GLP-1 receptor agonist pharmacology, peptide analytical chemistry (HPLC, mass spectrometry), clinical trial design interpretation, and UAE pharmaceutical regulatory frameworks including MoHAP Circular 17/2022.

For questions about specific articles or to discuss methodology, contact us via WhatsApp.

Source Hierarchy

Every factual claim in the research library is backed by at least one primary source. We prioritise sources in this order:

• Peer-reviewed publications — The New England Journal of Medicine, The Lancet, JAMA, Nature Medicine, and specialty journals. These are the gold standard for clinical efficacy and safety data.
• FDA filings and regulatory documents — NDA submissions, Prescribing Information labels, FDA approval letters, Breakthrough Therapy designations, and Advisory Committee briefing documents.
• ClinicalTrials.gov — Trial registrations, status updates, completion dates, and design protocols. Used to verify trial phase, enrollment, and current status.
• Company press releases and investor presentations — Used for pipeline timelines and regulatory filing dates when no peer-reviewed data is yet available. Always labeled as company-reported.
• Conference abstracts — ADA, ObesityWeek, EASD, and other medical conferences. Used for early data when full publication is pending.

What We Do Not Cite

• Social media posts, forums, or anecdotal reports
• Pre-print servers without peer review (unless explicitly noted)
• Animal studies presented as human evidence
• Marketing materials from pharmaceutical companies presented as clinical evidence
• Other peptide vendor websites

Claim Verification

Every article undergoes a structured review before publication:

• Data accuracy check — weight loss percentages, trial durations, sample sizes, and p-values are cross-referenced against the cited primary source
• Regulatory status check — approval claims are verified against FDA databases and ClinicalTrials.gov
• Date sensitivity check — time-bound claims (e.g. “not yet approved as of March 2026”) are flagged for regular updates
• Internal consistency check — data cited in one article is consistent with the same data cited in other articles across the library

Update Policy

Articles are updated when:

• New clinical trial results are published
• A regulatory decision changes the approval status of a compound
• An error or outdated claim is identified
• A reader reports a factual concern

Each article displays a visible Updated date in the byline and a collapsible Update History log showing what changed and when.

Editorial Independence

Remy Peptides is a research peptide supplier. Our research library covers compounds we do not sell (tirzepatide, semaglutide, CagriSema, survodutide, orforglipron, petrelintide, zenagamtide, mazdutide, VK2735) alongside the compound we do sell (retatrutide). We apply the same sourcing and verification standards to all compounds regardless of commercial interest.

Product references in articles are limited to a single footnote at the end of each article and are clearly separated from editorial content.

Corrections

If you find a factual error, outdated data point, or broken citation in any article, contact us via WhatsApp with the article URL and the specific claim in question. We review and correct confirmed errors within 48 hours. For full details on our author qualifications, fact-checking methodology, and correction policy, see our editorial policy.

Scope of Coverage

The research library currently covers 45 articles spanning the following therapeutic areas and compounds:

• Triple agonists — retatrutide (GLP-1/GIP/GCGR), including side effect profiles, head-to-head comparisons, and dosing protocols
• Dual agonists — tirzepatide (Mounjaro/Zepbound), survodutide, mazdutide — including our Mounjaro injection guide
• GLP-1 receptor agonists — semaglutide (Ozempic/Wegovy/Rybelsus), liraglutide (Saxenda) — covering injectable comparisons and oral formulations
• Amylin combinations — CagriSema, petrelintide, zenagamtide
• UAE market analysis — pricing, availability, regulatory landscape, and alternative therapies

Last reviewed: March 2026